Remove companies bristol-myers-squibb-co
article thumbnail

Bristol-Myers, Cruise Attys Among New USPTO Advisors

IP Law 360

Patent and Trademark Office on Friday announced the new members of its patent and trademark advisory committees, including attorneys from Bristol-Myers Squibb Co. and autonomous vehicle company Cruise.

article thumbnail

Understanding the Patent Linkage Process

IP and Legal Filings

Undoubtedly, pharmaceuticals companies will be the major supporter of the linkage framework to be adopted by countries, especially developing countries. The linkage framework will be inconsistent with the double benefits that pharmaceutical companies are getting with the prolonged market exclusivity for the drug.

Patent 78
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SpicyIP Weekly Review (August 16 – 22)

SpicyIP

Writing this post in the context of PV Sindhu’s success at the Tokyo Olympics and how that has spurred companies who do not sponsor her to put up congratulatory messages on social media with their brand logos and while using her images, Satchit analyses the discourse on the right to publicity surrounding the issue.

article thumbnail

Federal Circuit Panel Holds Hatch-Waxman Venue Under the Second Prong of § 1400(b) is Based on Actions Related to ANDA Submission

Fish & Richardson Trademark & Copyright Thoughts

7] If a branded company initiates an infringement action against a generic company within 45 days of receiving notice of ANDA submission, this triggers a 30-month stay during which FDA cannot issue a final approval for the ANDA. [8] If a branded company gets venue wrong, it risks a motion to dismiss for improper venue.

article thumbnail

trial court erred by presuming materiality of black box warning; $834 million penalty vacated

43(B)log

Bristol-Myers Squibb Co., 15, 2023) The state sued two pharmaceutical companies for violating Hawai‘i’s Unfair or Deceptive Acts or Practices law (UDAP) by misleading the public about the safety and efficacy of their antiplatelet drug, Plavix. State ex rel. 2023 WL 2519857, SCAP-21-0000363, P.3d 3d - (Hawai’i Mar.

Law 45